Xavier Michelet

Xavier Michelet holds extensive experience in the field of immunobiology and pharmacology, currently serving as Senior Investigator, Head of Pharmacology, and Director of Biology at AI Proteins since March 2023. Prior to this role, significant contributions were made at MiNK Therapeutics from March 2018 to March 2023, where responsibilities included leading preclinical studies in CAR-iNKT cell therapy, managing drug development strategy towards IND, and overseeing team performance. Previous positions include roles at Agenus, where expertise in T Cell Receptor therapies was developed, and multiple postdoctoral fellowships at Brigham and Women's Hospital and Harvard Medical School, focusing on natural killer cell mechanisms and immune response to bacterial infections. Education comprises a Ph.D. in Cell Biology from Paris-Sud University and a Master’s degree in Cancer research from the same institution.